Literature DB >> 20406662

Surveillance for adverse events following immunization (AEFI) in Switzerland--1991-2001.

Z Schumacher1, C Bourquin, U Heininger.   

Abstract

In Switzerland, reporting of adverse events following immunization (AEFI) has been mandatory by law since 1988. The goal of this study was a detailed analysis of reported AEFI received by the Swiss Federal Office of Public Health between 1991 and 2001. Overall, 1013 AEFI were reported which translates to 2.7 reports per 100,000 vaccine doses distributed during the study period. Most AEFI were classified as general systemic reactions (47%), followed by local (26%), neurological (16%) and allergic reactions (13%). The majority of all reported AEFI (N=513; 51%) had occurred in individuals 16 years and older. Causal relationship between immunization and AEFI was probable in 91 (10%) of 909 assessable reports and very likely or certain in 194 (21%), the majority of which (88%) were local reactions. Vaccines distributed in Switzerland have proven to be generally safe. Limitations of the passive surveillance system, however, warrant improvements in the future. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20406662     DOI: 10.1016/j.vaccine.2010.04.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Adverse events following immunization with oral poliovirus in Kinshasa, Democratic Republic of Congo: preliminary results.

Authors:  Didier Nzolo; Michel Ntetani Aloni; Thérèse Mpiempie Ngamasata; Bibiche Mvete Luemba; Sandrine Bazundama Marfeza; Mathilde Bothale Ekila; Célestin Ndosimao Nsibu; Narcisse Lutete Tona
Journal:  Pathog Glob Health       Date:  2013-10       Impact factor: 2.894

2.  Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China.

Authors:  Guodong Kang; Fenyang Tang; Zhiguo Wang; Ran Hu; Jing Yu; Jun Gao
Journal:  Hum Vaccin Immunother       Date:  2021-03-29       Impact factor: 3.452

3.  Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020.

Authors:  Yu Hu; Xuejiao Pan; Linzhi Shen; Fuxing Chen; Ying Wang; Hui Liang; Yaping Chen; Huakun Lv
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 4.526

Review 4.  Yellow fever vaccine-associated viscerotropic disease: current perspectives.

Authors:  Roger E Thomas
Journal:  Drug Des Devel Ther       Date:  2016-10-12       Impact factor: 4.162

5.  Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005-2017.

Authors:  Dongwon Yoon; Ju Hwan Kim; Hyesung Lee; Ju Young Shin
Journal:  Yonsei Med J       Date:  2020-07       Impact factor: 2.759

6.  Protectivity and safety following recombinant hepatitis B vaccine with different source of bulk compared to hepatitis B (Bio Farma) vaccine in Indonesia.

Authors:  Yetty M Nency; Farid Agung Rahmadi; Dimas Tri Anantyo; Nur Farhanah; Rebriarina Hapsari; Helmia Farida; Udadi Sadhana; Herry Djagat; Tri Nur Kristina; Achmad Zulfa Juniarto; Mita Puspita; Rini Mulia Sari; Novilia Sjafri Bachtiar
Journal:  Clin Exp Vaccine Res       Date:  2022-01-31

Review 7.  Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2016-06-20       Impact factor: 5.683

8.  Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017.

Authors:  F Moretti; L Gonella; S Gironi; A R Marra; C Santuccio; P Felicetti; F Petronzelli; P Marchione; S A Barnaba; A Poli; G Zanoni; U Moretti
Journal:  Sci Rep       Date:  2020-08-24       Impact factor: 4.379

Review 9.  A clinician's perspective on yellow fever vaccine-associated neurotropic disease.

Authors:  Elien Lecomte; Guy Laureys; Frederick Verbeke; Cristina Domingo Carrasco; Marjan Van Esbroeck; Ralph Huits
Journal:  J Travel Med       Date:  2020-11-09       Impact factor: 8.490

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.